MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Consensus "Hold": Sixteen brokerages rate MoonLake Immunotherapeutics an average of "Hold" (3 sell, 4 hold, 9 buy) with a mean 12‑month price target of $23.08.
• Insider selling: Major insiders have trimmed positions recently — BVF Partners sold 3,750,000 shares (~$62.96M at $16.79) and the CEO sold 98,127 shares (~$1.81M); insiders sold ~3.9M shares (~$65.7M) in the last 90 days and now own 12.02%.
• Key stock and financials: Shares trade near $16.73 with a market cap of $1.20B, a 12‑month range of $5.95–$62.75, reported Q (EPS) of ($0.92) meeting estimates, and analysts expect about -3.42 EPS for the year.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Hold" by the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $23.0769.

Several analysts have issued reports on MLTX shares. UBS Group set a $24.00 target price on shares of MoonLake Immunotherapeutics in a research note on Friday, January 9th. Oppenheimer boosted their target price on shares of MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research note on Tuesday, February 24th. Zacks Research raised shares of MoonLake Immunotherapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. Rothschild & Co Redburn raised shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $12.00 to $40.00 in a research note on Thursday, March 19th. Finally, Needham & Company LLC boosted their target price on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, February 23rd.

Insiders Place Their Bets

In other news, Director Bvf Partners L. P/Il sold 3,750,000 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $16.79, for a total value of $62,962,500.00. Following the transaction, the director directly owned 1,039,238 shares of the company's stock, valued at approximately $17,448,806.02. This represents a 78.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 98,127 shares of the company's stock in a transaction on Friday, April 10th. The stock was sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the completion of the transaction, the chief executive officer directly owned 2,976,766 shares in the company, valued at $54,802,262.06. This trade represents a 3.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,900,000 shares of company stock worth $65,714,663 over the last ninety days. 12.02% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of MoonLake Immunotherapeutics by 0.9% in the second quarter. Geode Capital Management LLC now owns 59,553 shares of the company's stock worth $2,809,000 after acquiring an additional 559 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of MoonLake Immunotherapeutics by 3.7% in the second quarter. Squarepoint Ops LLC now owns 17,571 shares of the company's stock worth $829,000 after acquiring an additional 629 shares during the last quarter. Axiom Investors LLC DE increased its stake in shares of MoonLake Immunotherapeutics by 3.2% in the fourth quarter. Axiom Investors LLC DE now owns 25,998 shares of the company's stock worth $343,000 after acquiring an additional 818 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock worth $45,000 after acquiring an additional 1,069 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company's stock worth $52,000 after acquiring an additional 1,158 shares during the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX opened at $16.73 on Friday. The company's fifty day moving average is $17.55 and its two-hundred day moving average is $14.96. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24. MoonLake Immunotherapeutics has a 12-month low of $5.95 and a 12-month high of $62.75. The company has a market cap of $1.20 billion, a P/E ratio of -4.75 and a beta of 1.02.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Wednesday, February 25th. The company reported ($0.92) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.92). During the same quarter last year, the company earned ($0.72) EPS. Equities analysts expect that MoonLake Immunotherapeutics will post -3.42 earnings per share for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.